Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.69 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.69 |
| ▸ | MAPK8 | P45983 | 12/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 5/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937783 | 1.00 | ROCK2 (0.69) | ROCK2ROCK1MAPK8KITFLT3 | |
| SCHEMBL1937533 | 0.90 | ROCK2 (0.55) | ROCK2ROCK1MAPK8KITFLT3 | |
| SCHEMBL1936224 | 0.90 | ROCK2 (0.55) | ROCK2ROCK1MAPK8KITFLT3 | |
| SCHEMBL1937536 | 0.90 | ROCK2 (0.55) | ROCK2ROCK1MAPK8KITFLT3 | |
| SCHEMBL1936225 | 0.90 | ROCK2 (0.55) | ROCK2ROCK1MAPK8KITFLT3 | |
| SCHEMBL1937142 | 0.89 | ROCK2 (0.54) | ROCK2ROCK1MAPK8KITFLT3 | |
| SCHEMBL1937146 | 0.89 | ROCK2 (0.54) | ROCK2ROCK1MAPK8KITFLT3 | |
| SCHEMBL1937890 | 0.88 | ROCK2 (0.53) | ROCK2ROCK1MAPK8KITFLT3 | |
| SCHEMBL1936715 | 0.88 | ROCK2 (0.53) | ROCK2ROCK1MAPK8KITFLT3 | |
| SCHEMBL1937891 | 0.88 | ROCK2 (0.53) | ROCK2ROCK1MAPK8KITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-2331507-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885MAPK8 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.